Cargando…

Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

BACKGROUND: Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. METHODS AND RESULTS: Using the National Inpatient Sample from January 2012 through December 2019, we identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Patlolla, Sri Harsha, Schaff, Hartzell V., Nishimura, Rick A., Eleid, Mackram F., Geske, Jeffrey B., Ommen, Steve R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973566/
https://www.ncbi.nlm.nih.gov/pubmed/36565202
http://dx.doi.org/10.1161/JAHA.122.026661
_version_ 1784898552827215872
author Patlolla, Sri Harsha
Schaff, Hartzell V.
Nishimura, Rick A.
Eleid, Mackram F.
Geske, Jeffrey B.
Ommen, Steve R.
author_facet Patlolla, Sri Harsha
Schaff, Hartzell V.
Nishimura, Rick A.
Eleid, Mackram F.
Geske, Jeffrey B.
Ommen, Steve R.
author_sort Patlolla, Sri Harsha
collection PubMed
description BACKGROUND: Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. METHODS AND RESULTS: Using the National Inpatient Sample from January 2012 through December 2019, we identified all adult admissions with a primary diagnosis of obstructive hypertrophic cardiomyopathy and those undergoing SRT. Predictors of receiving SRT and outcomes including in‐hospital mortality, complications, and resource use were evaluated in racial and ethnic groups. Among a total of 18 895 adult admissions with obstructive hypertrophic cardiomyopathy, SRT was performed in 7255 (38.4%) admissions. Septal myectomy was performed in 4930 (26.1%), while alcohol septal ablation was performed in 2325 (12.3%). In adjusted analysis, Black patient (versus White patient adjusted odds ratio, 0.65 [95% CI, 0.57–0.73]; P<0.001) and Hispanic patient admissions (versus White adjusted odds ratio, 0.78 [95% CI, 0.66–0.92]; P=0.003) were less likely to receive SRT. Among admissions undergoing SRT, in‐hospital mortality was significantly higher for Hispanic (adjusted odds ratio, 3.38 [95% CI, 1.81–6.30], P<0.001) and other racial and ethnic groups (adjusted odds ratio 2.02 [95% CI, 1.00–4.11]; P=0.05) compared with White patient admissions, whereas Black patient admissions had comparable mortality. Black, Hispanic, and other ethnic group patients had higher rates of SRT complications and more frequent dismissals to acute care facilities. CONCLUSIONS: Among obstructive hypertrophic cardiomyopathy hospitalizations, minoritized racial groups were less likely to receive SRT. Importantly, hospitalizations of Hispanic and other ethnic patients undergoing SRT had significantly higher in‐hospital mortality and complication rates. Further studies with granular echocardiographic information to assess indications for SRT are needed to better understand these differences.
format Online
Article
Text
id pubmed-9973566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99735662023-03-01 Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy Patlolla, Sri Harsha Schaff, Hartzell V. Nishimura, Rick A. Eleid, Mackram F. Geske, Jeffrey B. Ommen, Steve R. J Am Heart Assoc Original Research BACKGROUND: Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. METHODS AND RESULTS: Using the National Inpatient Sample from January 2012 through December 2019, we identified all adult admissions with a primary diagnosis of obstructive hypertrophic cardiomyopathy and those undergoing SRT. Predictors of receiving SRT and outcomes including in‐hospital mortality, complications, and resource use were evaluated in racial and ethnic groups. Among a total of 18 895 adult admissions with obstructive hypertrophic cardiomyopathy, SRT was performed in 7255 (38.4%) admissions. Septal myectomy was performed in 4930 (26.1%), while alcohol septal ablation was performed in 2325 (12.3%). In adjusted analysis, Black patient (versus White patient adjusted odds ratio, 0.65 [95% CI, 0.57–0.73]; P<0.001) and Hispanic patient admissions (versus White adjusted odds ratio, 0.78 [95% CI, 0.66–0.92]; P=0.003) were less likely to receive SRT. Among admissions undergoing SRT, in‐hospital mortality was significantly higher for Hispanic (adjusted odds ratio, 3.38 [95% CI, 1.81–6.30], P<0.001) and other racial and ethnic groups (adjusted odds ratio 2.02 [95% CI, 1.00–4.11]; P=0.05) compared with White patient admissions, whereas Black patient admissions had comparable mortality. Black, Hispanic, and other ethnic group patients had higher rates of SRT complications and more frequent dismissals to acute care facilities. CONCLUSIONS: Among obstructive hypertrophic cardiomyopathy hospitalizations, minoritized racial groups were less likely to receive SRT. Importantly, hospitalizations of Hispanic and other ethnic patients undergoing SRT had significantly higher in‐hospital mortality and complication rates. Further studies with granular echocardiographic information to assess indications for SRT are needed to better understand these differences. John Wiley and Sons Inc. 2022-12-24 /pmc/articles/PMC9973566/ /pubmed/36565202 http://dx.doi.org/10.1161/JAHA.122.026661 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Patlolla, Sri Harsha
Schaff, Hartzell V.
Nishimura, Rick A.
Eleid, Mackram F.
Geske, Jeffrey B.
Ommen, Steve R.
Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
title Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
title_full Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
title_fullStr Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
title_full_unstemmed Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
title_short Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
title_sort impact of race and ethnicity on use and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973566/
https://www.ncbi.nlm.nih.gov/pubmed/36565202
http://dx.doi.org/10.1161/JAHA.122.026661
work_keys_str_mv AT patlollasriharsha impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy
AT schaffhartzellv impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy
AT nishimuraricka impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy
AT eleidmackramf impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy
AT geskejeffreyb impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy
AT ommenstever impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy